Dr. Reddy’s Laboratories (NYSE:RDY) has launched Bortezomib for Injection 3.5 mg/vial, approved by the FDA for intravenous use only. It is indicated for the treatment of adult patients with multiple myeloma and for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.
The branded version is Takeda Pharmaceutical’s (NYSE:TAK) Velcade, administered IV and subcutaneously.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.